Deutsch Named Professor of the Practice
RWD Technologies and Robert W. Deutsch Foundation founder Dr. Robert W. Deutsch has been named a Professor of the Practice within the Fischell Department of Bioengineering. Deutsch was presented with the honor, citing his "distinguished career as a technologist and entrepreneur and for his friendship with and support of the University of Maryland" at a recent gathering to present the achievements of a nano-bio research initiative funded by the Deutsch Foundation.
Dr. Deutsch received a B.S. in physics from the Massachusetts Institute of Technology (M.I.T.) and a Ph.D. in high-energy physics from the University of California at Berkeley. He has been both an educator and innovator. After serving as Chief Professor of Nuclear Science and Engineering at The Catholic University of America, he founded General Physics Corporation, which trained operators of nuclear power plants; and later RWD Technologies, which serves the technology training and performance optimization needs of Fortune 500 companies worldwide. Dr. Deutsch is also a member of the National Academy of Engineering (NAE), a registered Professional Engineer, and a veteran of WWII.
Since 1992, the Deutsch Foundation has supported scholarships, organizations and research at the University of Maryland College Park and other schools within the University System of Maryland, including a $1 million pledge in 2006 to support nanoscale biological research at the Clark School. The cross-disciplinary nano-bio research group is developing a new "biochip" technology that promises to give doctors a new way to discover drugs to treat bacterial infections without stimulating resistance-building mutations. Team members include Clark School faculty William Bentley (Chair, Fischell Department of Bioengineering), Reza Ghodssi (electrical and computer engineering [ECE], Institute for Systems Research [ISR] and Maryland NanoCenter), and Gary Rubloff (Maryland NanoCenter, materials science and engineering [MSE], ECE and ISR), as well as colleagues in the University of Maryland, Baltimore School of Pharmacy and the University of Maryland Biotechnology Institute (UMBI).
For more information:
January 15, 2008